SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site), Unconjugated, Rabbit, Polyclonal

Catalog Number: PRS-9095
Article Name: SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site), Unconjugated, Rabbit, Polyclonal
Biozol Catalog Number: PRS-9095
Supplier Catalog Number: 9095
Alternative Catalog Number: PRS-9095-0.02,PRS-9095-0.1
Manufacturer: ProSci
Host: Rabbit
Category: Antikörper
Application: ELISA, IF, WB
Species Reactivity: Virus
Immunogen: Anti-SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) (9095) was raised against a peptide corresponding to 13 amino acids near the center of SARS-CoV-2 (COVID-19) Spike glycoprotein. The immunogen is located within 650-700 amino acids of SARS-CoV-2 (COVID-19) Spike protein.
Conjugation: Unconjugated
Alternative Names: SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Spike protein, Surface Glycoprotein, covid-19, sars-cov-2
Clonality: Polyclonal
Concentration: 1 mg/mL
NCBI: 43740568
UniProt: P0DTC2
Buffer: SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) is supplied in PBS containing 0.02% sodium azide.
Form: Liquid
Application Dilute: Optimal dilutions for each application to be determined by the researcher.
Application Notes: WB: 2.5-5 µg/mL, IF: 20 µg/mL.Antibody validated: Western Blot in human samples, Immunofluorescence in human samples. SARS-CoV-2 (COVID-19) Spike Antibody (cleavage site) can be used for the detection of SARS-CoV-2 (COVID-19) Spike protein in ELISA. It will detect 4 ng of free peptide at 1 µg/mL. All other applications and species not yet tested.
Figure 3 ELISA Validation with SARS-CoV-2 (COVID-19) Spike Recombinant ProteinAntibodies: SARS-CoV-2 (COVID-19) Spike antibody (cleavage site), 9095 (1 &956,g/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody (cleavage site) as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.
Figure 1 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike (cleavage site) in 293 Transfected CellsImmunofluorescent analysis of 4% paraformaldehyde-fixed 293 spike transfected cells labeling SARS-CoV-2 (COVID-19) Spike (cleavage site) with 9095 at 20 mg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
Figure 2 Overexpression Validation in Spike Transfected 293 Cells Loading: 15 &956,g per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9095 (4 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: WT 293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells
Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087. Antibodies: SARS-CoV-2 (COVID-19) Spike (cleavage site), 9095, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 2.5 µg/mL and Lane 2: 5 µg/mL.